DNA crosslinking damage and cancer - a tale of friend and foe
- PMID: 23998004
- PMCID: PMC3755464
- DOI: 10.3978/j.issn.2218-676X.2013.03.01
DNA crosslinking damage and cancer - a tale of friend and foe
Abstract
Interstrand crosslinks (ICLs) represent a major challenge for DNA replication and transcription by preventing DNA strand separation. Cells deficient in ICL repair are hypersensitive to a variety of bifunctional alkylating agents and exhibit excessive genomic instability. Patients with deficient ICL repair, such as those with Fanconi anemia, are predisposed to a broad spectrum of cancers. The profound cellular toxicity of ICLs is exploited clinically in cancer chemotherapy. Therefore, understanding the mechanism of ICL repair and its impact on cancer development and treatment is very important. Studies of diseases with defective ICL repair, especially Fanconi anemia, have revealed unique ICL repair mechanisms in humans. In this review, we describe pathways and factors involved in ICL damage response and their implications in cancer development and treatment.
Keywords: DNA repair; Fanconi anemia; Interstrand crosslink; cancer.
Conflict of interest statement
Figures
References
-
- O'Donovan A, Davies AA, Moggs JG, et al. XPG endonuclease makes the 3' incision in human DNA nucleotide excision repair. Nature. 1994;371:432–435. - PubMed
-
- Goodman LS, Wintrobe MM. Nitrogen mustard therapy; use of methyl-bis (beta-chloroethyl) amine hydrochloride and tris (beta-chloroethyl) amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders. J Am Med Assoc. 1946;132:126–132. - PubMed
-
- McVey M. Strategies for DNA interstrand crosslink repair: insights from worms, flies, frogs, and slime molds. Environ Mol Mutagen. 2010;51:646–658. - PubMed
-
- Lawley PD, Phillips DH. DNA adducts from chemotherapeutic agents. Mutat Res. 1996;355:13–40. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources